Keynote Speakers

Jonny Imerman

Jonny Imerman
8:30 am Saturday November 13th 
Survivors and Caregivers Turning Pain into Purpose



Jonny Imerman is the founder of Imerman Angels. While fighting cancer at 26 years old, Jonny had loving support from family and friends, but never met anyone his age who was a cancer survivor. He wanted to talk to someone just like him, someone who truly understood and remembered – someone who had already faced the same type of cancer.

Today, Imerman Angels provides that gift for cancer fighters. Imerman Angels introduces each cancer fighter to one survivor who is the same age, same gender, and someone who has already faced that particular type of cancer. A cancer survivor would be an angel – walking, talking, living proof to inspire the fighter that he/she can overcome their cancer. This was the beginning of Jonny’s vision. In 2006, Imerman Angels was founded.

Dr. Richard Gorlick

Dr. Richard Gorlick
Dr. Richard Gorlick is a Pediatric Hematologist-Oncologist in Houston, Texas at The University of Texas MD Anderson Cancer Center. He is Division Head and Department Chair of Pediatrics, Department Chair ad interim of Sarcoma Medical Oncology in the Division of Cancer Medicine, and H. Grant Taylor, M.D., W. W. Sutow, M.D. and Margaret P. Sullivan, M.D. Distinguished Chair in Pediatrics at MD Anderson. Prior to joining MD Anderson, Dr. Gorlick served as Division Chief of Pediatric Hematology-Oncology and Vice Chairman of Pediatrics at The Children’s Hospital at Montefiore, as well as Professor of Pediatrics and Molecular Pharmacology at Albert Einstein College of Medicine. He received his medical degree from State University of New York Downstate Medical Center College of Medicine and has been in practice for more than 20 years. He trained at New York-Presbyterian and Memorial Sloan-Kettering Cancer Center, where he began his sarcoma research laboratory and clinical practice.

Friday, November 12th, 9:00 am
Maximizing Health, Wellness and Productivity in Survivors of Childhood and Adolescent Cancer
  

A pediatric cancer survivor himself, Dr. Gorlick committed his life’s work to helping young patients and their families. For more than two decades, his research and clinical efforts have centered on sarcomas. His early involvement in the Children’s Oncology Group (COG) established the founding Bone Tumor Resource Laboratory, which has become a national resource and home to the world’s largest osteosarcoma tissue bank. Additionally, his molecular pharmacology laboratory is focused on osteosarcoma and is a member of the NCI-funded Pediatric Preclinical Testing Consortium.

Dr. Gorlick has served as an active member, advisor, and leader in a number of organizations, including the National Cancer Institute’s Pediatric Preclinical Testing Consortium, the Sarcoma Alliance for Research through Collaboration Consortium, and the COG. Dr. Gorlick is involved in clinical trials, in part, as past chair of the Bone Tumor Disease Committee for COG. He is also a past president of the Connective Tissue Oncology Society.

Dr. Gorlick has published more than 299 peer-reviewed papers, reviews and book chapters.

Dr. Andy Livingston

Dr. Andy Livingston

Friday, November 12th, 9:00 am
Maximizing Health, Wellness and Productivity in Survivors of Childhood and Adolescent Cancer
CO-Presenter

 

Dr. Livingston is a clinician and researcher in Sarcoma Medical Oncology and holds a joint appointment in Pediatric Oncology. After completing medical school at the University of Texas Medical Branch at Galveston, he went on to residency training at Duke University where he completed a combined residency in internal medicine and pediatrics. Dr. Livingston completed his fellowship training here at MD Anderson where he served as the Chief Fellow for Hematology/Oncology Fellowship Program. Dr. Livingston has a particular interest in the care of teens and young adults with cancer and is Co-director of the MD Anderson Adolescent and Young Adult (AYA) oncology program. His clinical and translational research is focused on developing new treatment strategies for patients with osteosarcoma and other bone sarcomas.